Tango Therapeutics, Inc.

Tango Therapeutics upgraded from 'Hold' to 'Buy' following strong phase 1/2 data for vopimetostat + RASONQUE in MTAP-del, 2nd-line/3rd-line RAS-mutant PDAC. Company's combination therapy showed an 82% ORR and 88% 9-month PFS, with median PFS not yet reached, supporting advancement to phase 3. Phase 3 registrational trial for 1st-line patients is anticipated in 1H 2027, with potential accelerated approval pathway for 2nd-line patients possible.

Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer, outperforming historical controls. I view the ESMO-driven sell-off as overdone, given TNGX's strong cash position ($1B), FDA-aligned registrational design, and underappreciated dual-primary endpoint trial. Vopimetostat enables daraxonrasib dose-sparing, reducing toxicity and cost, making TNGX a preferred RAS combination partner with expanding partnership optionality.

Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript